NO301215B1 - Fremgangsmåte for fremstilling av en vandig suspensjon av 5-(3-etoksy-4-n-pentyloksyfenyl)tiazolidin-2,4-dion - Google Patents
Fremgangsmåte for fremstilling av en vandig suspensjon av 5-(3-etoksy-4-n-pentyloksyfenyl)tiazolidin-2,4-dion Download PDFInfo
- Publication number
- NO301215B1 NO301215B1 NO924549A NO924549A NO301215B1 NO 301215 B1 NO301215 B1 NO 301215B1 NO 924549 A NO924549 A NO 924549A NO 924549 A NO924549 A NO 924549A NO 301215 B1 NO301215 B1 NO 301215B1
- Authority
- NO
- Norway
- Prior art keywords
- solution
- water
- aqueous suspension
- pentyloxyphenyl
- thiazolidine
- Prior art date
Links
- CRPGRUONUFDYBG-UHFFFAOYSA-N risarestat Chemical compound C1=C(OCC)C(OCCCCC)=CC=C1C1C(=O)NC(=O)S1 CRPGRUONUFDYBG-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 239000007900 aqueous suspension Substances 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title abstract description 6
- 239000000243 solution Substances 0.000 claims abstract description 39
- 239000007864 aqueous solution Substances 0.000 claims abstract description 20
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 17
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 17
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 10
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract description 9
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 9
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract description 8
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims abstract description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 8
- 229920000609 methyl cellulose Polymers 0.000 claims abstract description 7
- 239000001923 methylcellulose Substances 0.000 claims abstract description 7
- 235000010981 methylcellulose Nutrition 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 229920002521 macromolecule Polymers 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 abstract description 2
- 229940012356 eye drops Drugs 0.000 abstract description 2
- 239000013081 microcrystal Substances 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 4
- 206010007749 Cataract diabetic Diseases 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- -1 alkali metal salt Chemical class 0.000 description 3
- 210000004081 cilia Anatomy 0.000 description 3
- 201000007025 diabetic cataract Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229940037001 sodium edetate Drugs 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- DHNGCHLFKUPGPX-RMKNXTFCSA-N ethyl trans-p-methoxycinnamate Chemical compound CCOC(=O)\C=C\C1=CC=C(OC)C=C1 DHNGCHLFKUPGPX-RMKNXTFCSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Lasers (AREA)
- Lighting Device Outwards From Vehicle And Optical Signal (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6290991 | 1991-03-27 | ||
| PCT/JP1991/000932 WO1992017174A1 (en) | 1991-03-27 | 1991-07-11 | Process for preparing aqueous suspension |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO924549L NO924549L (no) | 1992-11-25 |
| NO924549D0 NO924549D0 (no) | 1992-11-25 |
| NO301215B1 true NO301215B1 (no) | 1997-09-29 |
Family
ID=13213855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO924549A NO301215B1 (no) | 1991-03-27 | 1992-11-25 | Fremgangsmåte for fremstilling av en vandig suspensjon av 5-(3-etoksy-4-n-pentyloksyfenyl)tiazolidin-2,4-dion |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5366985A (de) |
| EP (1) | EP0531529B1 (de) |
| KR (1) | KR0181973B1 (de) |
| AT (1) | ATE145328T1 (de) |
| AU (2) | AU650889B2 (de) |
| CA (1) | CA2083842A1 (de) |
| DE (1) | DE69123248T2 (de) |
| DK (1) | DK0531529T3 (de) |
| ES (1) | ES2094227T3 (de) |
| FI (1) | FI100694B (de) |
| NO (1) | NO301215B1 (de) |
| RU (1) | RU2098094C1 (de) |
| TW (1) | TW207500B (de) |
| WO (1) | WO1992017174A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1284030B1 (it) * | 1996-06-18 | 1998-05-08 | Solchem Italiana Spa | Metodo per la produzione di sospensioni acquose stabili, utili nelle composizioni farmaceutiche |
| CA2289618A1 (en) | 1997-05-14 | 1998-11-19 | Shin-Ichi Yasueda | Aqueous suspension preparations with excellent redispersibility |
| US6858230B1 (en) * | 1999-04-12 | 2005-02-22 | Shionogi & Co., Ltd. | Process for producing medicinal composition of basic hydrophobic medicinal compound |
| CA2839847C (en) * | 2003-06-13 | 2016-03-15 | Masood A. Chowhan | Ophthalmic compositions containing a synergistic combination of two polymers |
| US7947295B2 (en) | 2003-06-13 | 2011-05-24 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of two polymers |
| TWI363626B (en) * | 2004-11-15 | 2012-05-11 | Otsuka Pharma Co Ltd | Aqueous ophthalmic suspension of crystalline rebamipide |
| WO2007058935A2 (en) * | 2005-11-14 | 2007-05-24 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| TW200808375A (en) * | 2006-05-12 | 2008-02-16 | Otsuka Pharma Co Ltd | Hydrogel suspension and manufacturing process thereof |
| TWI415629B (zh) * | 2006-10-26 | 2013-11-21 | Otsuka Pharma Co Ltd | 含有瑞巴匹特之水性醫藥懸浮物及其製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6610081A (en) * | 1980-01-24 | 1981-07-30 | Senju Pharmaceutical Co., Ltd. | Thiazolidine derivatives |
| JPS6143114A (ja) * | 1984-08-03 | 1986-03-01 | Takeda Chem Ind Ltd | 虹彩・毛様体疾患治療用眼局所投与剤 |
| US5192535A (en) * | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
-
1991
- 1991-07-11 EP EP91912370A patent/EP0531529B1/de not_active Expired - Lifetime
- 1991-07-11 CA CA002083842A patent/CA2083842A1/en not_active Abandoned
- 1991-07-11 ES ES91912370T patent/ES2094227T3/es not_active Expired - Lifetime
- 1991-07-11 DE DE69123248T patent/DE69123248T2/de not_active Expired - Fee Related
- 1991-07-11 DK DK91912370.3T patent/DK0531529T3/da active
- 1991-07-11 RU RU9292016488A patent/RU2098094C1/ru active
- 1991-07-11 WO PCT/JP1991/000932 patent/WO1992017174A1/ja active IP Right Grant
- 1991-07-11 AU AU81047/91A patent/AU650889B2/en not_active Ceased
- 1991-07-11 AT AT91912370T patent/ATE145328T1/de not_active IP Right Cessation
- 1991-07-11 US US07/946,443 patent/US5366985A/en not_active Expired - Fee Related
- 1991-07-11 KR KR1019920702981A patent/KR0181973B1/ko not_active IP Right Cessation
- 1991-07-13 TW TW080105455A patent/TW207500B/zh active
-
1992
- 1992-11-25 FI FI925353A patent/FI100694B/fi active
- 1992-11-25 NO NO924549A patent/NO301215B1/no unknown
-
1994
- 1994-05-04 AU AU61888/94A patent/AU661944B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FI925353A (fi) | 1992-11-25 |
| FI100694B (fi) | 1998-02-13 |
| NO924549L (no) | 1992-11-25 |
| DE69123248D1 (de) | 1997-01-02 |
| WO1992017174A1 (en) | 1992-10-15 |
| TW207500B (de) | 1993-06-11 |
| KR0181973B1 (ko) | 1999-05-01 |
| EP0531529A4 (en) | 1993-08-04 |
| KR930700097A (ko) | 1993-03-13 |
| DE69123248T2 (de) | 1997-03-13 |
| AU6188894A (en) | 1994-06-30 |
| CA2083842A1 (en) | 1992-09-28 |
| AU661944B2 (en) | 1995-08-10 |
| AU8104791A (en) | 1992-11-02 |
| ATE145328T1 (de) | 1996-12-15 |
| ES2094227T3 (es) | 1997-01-16 |
| AU650889B2 (en) | 1994-07-07 |
| FI925353A0 (fi) | 1992-11-25 |
| RU2098094C1 (ru) | 1997-12-10 |
| EP0531529B1 (de) | 1996-11-20 |
| US5366985A (en) | 1994-11-22 |
| EP0531529A1 (de) | 1993-03-17 |
| NO924549D0 (no) | 1992-11-25 |
| DK0531529T3 (da) | 1997-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2954642B2 (ja) | 眼科用製剤の保存システム | |
| TWI791438B (zh) | 含阿托平之水性組成物 | |
| CN110664757B (zh) | 纳米晶滴眼剂、其制备方法及其应用 | |
| JPH054918A (ja) | 安定な水性製剤 | |
| NO177845B (no) | Fremgangsmåte for fremstilling av et preparat for öyedråper | |
| JPH02264716A (ja) | トラニラスト水溶液製剤 | |
| US5314909A (en) | Use of non-steroidal antiiflammatory agents in macular degeneration | |
| CA2447562A1 (en) | Pirenzepine ophthalmic gel | |
| NO301215B1 (no) | Fremgangsmåte for fremstilling av en vandig suspensjon av 5-(3-etoksy-4-n-pentyloksyfenyl)tiazolidin-2,4-dion | |
| JPH03133936A (ja) | 蛋白質ゲル状眼用賦形剤 | |
| CN111821261B (zh) | 用于制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法 | |
| JP2967523B2 (ja) | 眼病用製薬組成物 | |
| JP2808378B2 (ja) | 水性懸濁液剤の製造法 | |
| JPH0930966A (ja) | 眼科用新規製剤 | |
| JP2787131B2 (ja) | 水性懸濁液剤 | |
| CN104027302B (zh) | 17α-乙炔基雄甾-5-烯-3β,7β,17β-三醇眼用制剂 | |
| TWI428128B (zh) | 含有西洛施大唑（ｃｉｌｏｓｔａｚｏｌ）之環糊精包絡化合物為有效成分之青光眼治療劑 | |
| AU2014274955A1 (en) | Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease | |
| WO1993023032A1 (en) | Remedy for cataract and production thereof | |
| CN115487139B (zh) | 一种葛根素结冷胶离子型原位凝胶滴眼液及制备方法 | |
| RU2434633C2 (ru) | Фармацевтические препаративные формы латрункулина | |
| CN111346050A (zh) | 盐酸地巴唑滴眼液及其制备方法 | |
| CA2248881A1 (en) | Ophthalmological composition of the type which undergoes liquid-gel phase transition | |
| CN116570558B (zh) | 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用 | |
| RU2038076C1 (ru) | Местно-анестезирующее средство для глаз |